Vantrexa · NSCLC · United Kingdom · Thoracic medical oncologist · captured by James Whitfield on 11 Aug 2026 · reviewed by Dr. Elena Moretti on 17 Aug 2026
Verbatim as captured; never edited
Thoracic medical oncologist at Royal Marsden raised brain-metastasis subgroup data during a scientific exchange. They indicated this influences their current prescribing approach.
Human-approved by Dr. Elena Moretti on 17 Aug 2026
Brain-metastasis subgroup data: request for data reported by thoracic medical oncologist (GB).
helixor-private-llm-2026.08 · generated 11 Aug 2026, 10:00 UTC
AI summary
Brain-metastasis subgroup data raised by thoracic medical oncologist; aligns with Medical Affairs.
Source spans used by the model
Thoracic medical oncologist at Royal Marsden raised brain-metastasis subgroup data during a scientific exchange. They indicated this influences their current prescribing approach.
| Field | AI suggestion | Final (human-approved) |
|---|---|---|
| Category | Evidence gap | Treatment pathway |
| Function | Medical Affairs | Medical Affairs |
| Priority | Medium | Medium |
Transparent weighted model; contribution = value ÷ 5 × weight
| Dimension | Value (1–5) | Weight | Contribution |
|---|---|---|---|
| Patient relevance | 4 | 20% | 16.0 |
| Strategic alignment | 1 | 20% | 4.0 |
| Scientific importance | 5 | 15% | 15.0 |
| Urgency | 2 | 15% | 6.0 |
| Novelty | 5 | 10% | 10.0 |
| Actionability | 1 | 10% | 2.0 |
| Confidence | 3 | 5% | 3.0 |
| Breadth of occurrence | 2 | 5% | 2.0 |
| Total | Medium 58 | ||
No audit events in sample data
Every model call on this record and its human outcome
No AI interactions in sample data
Current stage and the next allowed action
Who reviewed, what action, which function, what decision, what outcome, when closed
11 Aug 2026 · Dr. Liam Quinn, Royal Marsden · MSL James Whitfield
Insight
Reviewed 17 Aug 2026 by Dr. Elena Moretti
Action
Initiative
Decision
Outcome
Closure